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Abstract
Background: Sailuotong (SLT) is a standardised herbal medicine formula consisting of Panax ginseng,
Ginkgo biloba, and Crocus sativus, and has been designed to enhance cognitive and cardiovascular function.
Methods: Using a randomised, double-blind, placebo controlled crossover design, this pilot study assessed the
effect of treatment for 1 week with SLT and placebo (1 week washout period) on neurocognitive and
cardiovascular function in healthy adults. Sixteen adults completed a computerised neuropsychological test
battery (Compass), and had their electroencephalographic (EEG) activity and cardiovascular system function
assessed. Primary outcome measures were cognitive test scores and oddball task event-related potential (ERP)
component amplitudes. Secondary outcome measures were resting EEG spectral band amplitudes, and
cardiovascular parameters. Results: Treatment with SLT, compared to placebo, resulted in small
improvements in working memory, a slight increase in auditory target (cf. nontarget) P3a amplitude, and a
decrease in auditory N1 target (cf. nontarget) amplitude. There was no effect of SLT on EEG amplitude in
delta, theta, alpha, or beta bands in both eyes open and eyes closed resting conditions, or on aortic and
peripheral pulse pressure, and resting heartrate. Conclusions: Findings suggest that SLT has the potential to
improve working memory performance in healthy adults; a larger sample size is needed to confirm this. Trial
registration: Australia New Zealand Clinical Trials Registry Trial Registration Id: ACTRN12610000947000.
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The effect of Sailuotong (SLT) on
neurocognitive and cardiovascular function
in healthy adults: a randomised, double-
blind, placebo controlled crossover pilot
trial
Genevieve Z. Steiner1,2†, Alan Yeung1†, Jian-Xun Liu3, David A. Camfield4,5, Frances M. de Blasio2,
Andrew Pipingas4, Andrew B. Scholey4, Con Stough4 and Dennis H. Chang1*
Abstract
Background: Sailuotong (SLT) is a standardised herbal medicine formula consisting of Panax ginseng, Ginkgo biloba,
and Crocus sativus, and has been designed to enhance cognitive and cardiovascular function.
Methods: Using a randomised, double-blind, placebo controlled crossover design, this pilot study assessed the
effect of treatment for 1 week with SLT and placebo (1 week washout period) on neurocognitive and cardiovascular
function in healthy adults. Sixteen adults completed a computerised neuropsychological test battery (Compass), and
had their electroencephalographic (EEG) activity and cardiovascular system function assessed. Primary outcome
measures were cognitive test scores and oddball task event-related potential (ERP) component amplitudes.
Secondary outcome measures were resting EEG spectral band amplitudes, and cardiovascular parameters.
Results: Treatment with SLT, compared to placebo, resulted in small improvements in working memory, a slight
increase in auditory target (cf. nontarget) P3a amplitude, and a decrease in auditory N1 target (cf. nontarget)
amplitude. There was no effect of SLT on EEG amplitude in delta, theta, alpha, or beta bands in both eyes open
and eyes closed resting conditions, or on aortic and peripheral pulse pressure, and resting heartrate.
Conclusions: Findings suggest that SLT has the potential to improve working memory performance in healthy
adults; a larger sample size is needed to confirm this.
Trial registration: Australia New Zealand Clinical Trials Registry Trial Registration Id: ACTRN12610000947000.
Keywords: Sailuotong (SLT), Chinese Herbal Medicine (CHM), EEG, Event-related potentials (ERPs), P3(00), Blood
pressure, Heartrate (HR), Neurocognition, Age related cognitive decline
Background
Most individuals experience a normal age-related decline
in a range of cognitive abilities including a decrease in in-
formation processing speed, and learning and memory
abilities [1]. For instance, cross-sectional studies have
demonstrated that working memory ability decreases
across most of the adult lifespan, with sharper declines
after 70 years of age [2]. Management of age-related
changes in cognition can be challenging as symptoms can
closely overlap with early stages of dementia, such as Alz-
heimer’s disease, which has a different pathophysiology;
for example, the presence of neurofibrillary tangles and
beta-amyloid plaques [3].
The ageing process can also be associated with neuro-
logical pathology [4], particularly at a cellular level. For in-
stance, a loss of synaptic density can contribute to a
reduction in regional brain volume and cortical thickness
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[5–7], with some regions that are responsible for advanced
cognition (e.g., working memory), including the prefrontal
cortex, showing a steady decline after the age of 20 [1].
Other factors linked to age-related cognitive decline (and
possibly the pathogenesis of dementia) include changes in
brain metabolite concentrations, inflammation, oxidative
stress, brain vascular integrity, and poor circulation, which
may be associated with a number of disease-related and
lifestyle-related risk factors such as diabetes, cardiovascu-
lar disease, obesity, and excessive alcohol consumption
[8–12].
In order to minimise the functional impairment asso-
ciated with the ageing process, particularly slowing,
stabilising, or (possibly) reversing cognitive decline, there
is a demand for appropriate pharmacological interven-
tions. Currently, there are few pharmaceutical options
available for otherwise healthy individuals, and these are
usually prescribed under the assumption of a patho-
physiological relationship between cognitive decline and
dementia [13]. For example, acetylcholinesterase (AChE)
inhibitors (e.g., donepezil) act on the enzyme which
breaks down acetylcholine, increasing its availability in
the synapses [14]; and N-methyl-D-asparate (NMDA)
glutamate receptor antagonists (e.g., memantine) nor-
malise the glutamatergic system by blocking NMDA
glutamate receptors [15]. There is little evidence to
suggest that these pharmacological approaches can
effectively treat forms of cognitive decline other than
dementia, including mild cognitive impairment [16–18]
which is often considered the prodromal phase for
Alzheimer’s disease [13]. AChE inhibitors are also
poorly tolerated, with adverse side effects related to cho-
linergic hyperactivity including bradycardia, hypotension,
gastrointestinal disturbances, vomiting, and bronchocon-
striction [19], making their implementation ethically un-
sound in populations that are otherwise unimpaired [20].
Further, the global changes associated with age-related
cognitive decline mentioned above indicate the need for
multi-target [21], rather than single-target treatments.
Where standard pharmaceuticals often utilise a single-
target approach (e.g., AChE inhibitors), complementary
medicine treatments, such as Chinese Herbal Medicine
(CHM), apply a multisystem approach in which combin-
ation multi-target therapies are used to treat disease
[22]. Complex herbal formulations used in CHM can
also have a synergistic effect, where additional extrac-
tions increase the efficacy of the formula as a whole
[23–27]. Given this approach, CHM may be more suit-
able in the treatment of age-related cognitive decline,
and is well-suited for chronic interventions due to accu-
mulative effects on multiple systems over a period of
time. Further, early research suggests that some herbal
formulations can enhance memory function and increase
longevity [28].
Sailuotong (SLT) is a new standardised three-herb
formula that combines specific doses of the key bioactive
constituents from the concentrated extracts of Panax
ginseng (ginsenosides), Ginkgo biloba (flavone-glyco-
sides), and Crocus sativus (crocins), and has been devel-
oped to enhance cognitive and cardiovascular function
through multiple pathways of action based on a compre-
hensive review of the CHM and medical literature. The
three herbal constituents have each demonstrated neu-
roprotective, antioxidant, and anti-hypertensive prop-
erties [29–32], and preliminary research suggests the
possibility of an enhanced therapeutic effect due to
synergism [23–25].
Preclinical pharmacokinetic, pharmacodynamic, and
toxicity studies have been conducted on these three
herbs separately, and in combination [29–38]. Treatment
with SLT in various experimental ischemia and amnesia
models in rodents resulted in improved learning and
memory function, antioxidant capacity, and pathogenic
biochemical blood and brain tissue parameters. For
example, over an eight week period, SLT decreased the
latency for finding the platform in a Morris Water Maze
in rats with chronic cerebral hypoperfusion model
induced by bilateral common carotid artery ligation [35].
Brain tissue cholinesterase decreased and acetylcholine
levels increased, and importantly, superoxide dismutase
(an enzyme that acts as an antioxidant) also increased.
In a similar investigation using an amyloid beta-protein
induced dementia model in mice [36], brain tissue
acetylcholine increased by 18.56 and 19.97 %, respect-
ively, when treated for 30 days with low (15.5 mg/kg)
and high (31.0 mg/kg) doses of SLT. Another study
using a PDAPPv7171 transgenic dementia model in mice
showed that treatment for 12 weeks with both low
(31 mg/kg) and high (62 mg/kg) doses of SLT increased
brain tissue acetylcholine levels [31]; brain tissue sero-
tonin levels decreased in the high dosage group only.
A range of cardiovascular benefits of SLT have also
been demonstrated [29, 30, 33]. Acute treatment over
24 h decreased the areas of focal cerebral ischemia/re-
perfusion injury in mice, and increased cerebral blood
flow was also observed 60–180 min after administration
(10 mg/kg) [33]. Rats also showed a decrease in platelet
aggregation rate and whole blood viscosity after treat-
ment with low (8 mg/kg) and high (16 mg/kg) doses of
SLT for 7 days.
In humans, a 16 week pilot study of SLT was
conducted on individuals with probable or possible
vascular dementia [38]. Participants treated with SLT
showed a significant improvement in Alzheimer’s Dis-
ease Assessment Scale cognitive subscale (ADAS-cog)
scores compared to placebo. Participants also reported
significant improvements in quality of life (Short Form
Health Survey; SF-36) related to emotional and physical
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role functioning, mental health, and social functioning.
A subset of participants also underwent single photon
emission computed tomography (SPECT) scan, which
demonstrated that those treated with SLT, compared to
placebo, showed increased blood flow in the inferior
frontal and anterior temporal lobes, which was greater
in the left hemisphere. This is a particularly promising
finding, as those regions are associated with memory
function, and auditory and speech processing.
Due to the lack of treatment options available for age-
related cognitive decline, and SLT’s potential to improve
cognitive and cardiovascular function, a trial of SLT on
healthy individuals is warranted. The current pilot study
employed a randomised, double-blind, placebo controlled
crossover design, and aimed to provide preliminary data
on the possible cognitive and cardiovascular benefits of
SLT in healthy adults. Neurocognitive function was
assessed using a computerised cognitive test battery, odd-
ball task event-related potential (ERP) component ampli-
tudes, and resting EEG spectral band amplitudes.
Cardiovascular system function measures were central
and peripheral pulse pressure, and resting heartrate (HR).
It was hypothesised that treatment for 1 week with SLT
would improve neurocognitive and cardiovascular func-
tion compared to placebo.
Methods
Inclusion criteria
Sixteen adults were recruited from students, staff, and
their families at Western Sydney University through ad-
vertisements on campus. All provided informed consent
and were advised that they were free to withdraw at any
time without penalty. Participants were excluded if they
were pregnant, obese (to reduce the chance of recruiting
participants with associated chronic diseases), had a his-
tory of allergies, serious gastrointestinal disorders,
asthma or serious pulmonary disorders, diabetes, or any
significant abnormality on laboratory tests including full
blood count, liver, and renal function. Any participants
taking anti-coagulant or cognitive enhancing medica-
tion/substances, including over the counter Ginkgo
biloba or Panax ginseng capsules, were also excluded.
All participants were non-smokers and showed no signs
of neurological impairment (mini mental state exam;
MMSE > 28).
Treatments
SLT treatment: SLT formula is standardised by the bio-
active components of the three herbal extracts from
Panax ginseng, Ginkgo biloba, and Crocus sativa. A
range of in vivo pharmacological studies have been
undertaken to test the bioactivity and determine the
optimal ratio of the three individual herbal extracts.
Each SLT capsule contains a 60 mg standardised mixture
of 27.27 mg ginsenosides from Panax ginseng, 27.27 mg
total ginkgo flavone-glycosides from Ginkgo biloba, and
5.46 mg crocins from Crocus sativa. The SLT prepara-
tions were manufactured in a Good Manufacturing Prac-
tice certified facility.
Placebo: Two capsules per day, containing an inert sub-
stance matched for the colour, taste, and smell of SLT.
Design
This pilot study employed a randomised, placebo con-
trolled, double-blind crossover design. Participants were
required to orally ingest two capsules of either SLT or a
placebo every day for one week. This was followed by a
one week washout period and the subsequent counter-
balanced treatment week. This washout period length
was determined by preclinical pharmacokinetic studies
[33]. The active herbal formulation and placebo were
prepared in an extract capsule form in accordance with
Australian Goods Manufacturing Practices. Neurocogni-
tive and cardiovascular function were tested before and
after each of the interventions. Primary outcome mea-
sures included neurocognitive function test scores,
and ERP component amplitudes. Secondary outcome
measures were EEG spectral band amplitudes, aortic
and peripheral pulse pressure, and resting HR. The
procedure was approved by Western Sydney Universi-
ty's Human Research Ethics Committee (Ethics Ap-
proval: H8253), and the trial was registered with the




Cognitive function was tested using the Computerised
Mental Performance Assessment System (Compass)
neuropsychological test battery, which measures a range
of cognitive abilities including attention, episodic mem-
ory, and working memory. These cognitive domains
were assessed using 12 Compass tasks: Immediate Word
Recall, Delayed Word Recall, Word Recognition, Simple
Reaction Time, Choice Reaction Time, Numeric Work-
ing Memory, Alphabetic Working Memory, Corsi Block
Span, N-Back Working Memory, Picture Recognition,
Face Recognition, Serial Subtraction, and Rapid Visual
Information Processing (RVIP). Parallel versions of each
task were used for the repeated testing sessions.
Mental fatigue and Mood were self-reported on a
Visual Analogue Scale (VAS) using a 100 mm horizontal
line displayed on a computer monitor, with each end-
point marking the two extremes of mental fatigue or
mood; participants responded using a computer mouse
cursor. Three dimensions of mood were assessed (alert-
ness, calmness, and contentment) with 16 separate
Bond-Lader VAS items [39].
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Electroencephalograph (EEG)
EEG data were recorded continuously from 18 scalp
sites (F1, F3, Fz, F2, F4, C1, C3, Cz, C2, C4, P1, P3, Pz,
P2, P4, O1, Oz, O2) with a 64 channel electrode cap
using sintered Ag/AgCl electrodes. The nose was used
as a reference and the cap was grounded by an electrode
located midway between AF3 and AF4. Data were
acquired 0–200 Hz using a Neuroscan Synamps 2 digital
signal-processing system and Neuroscan 4.3.1 Acquire
software. The display and stimulus markers were con-
trolled by a separate stimulus computer (Dell Optiplex
760 with a 22 " LG Flatron W2253TQ screen) using
Compumedics Stim2 (4.0.09302005) software.
Electro-oculogram (EOG) was recorded using sintered
Ag/AgCl electrodes placed 2 cm above and below the
left eye for vertical movements, and on the outer can-
thus of each eye for horizontal movements. Impedance
was less than 10 kΩ for cap, EOG, and reference elec-
trodes. Scalp and EOG potentials were amplified with a
gain of 2816 and digitised at 1000 Hz.
EEG was recorded during two resting conditions
(5 min eyes open and 5 min eyes closed) followed by
two oddball tasks (visual then auditory). For the visual
oddball task, stimuli were white 37 × 43 mm letters
(target: X; nontarget: O) presented for 500 ms on a black
background. For the auditory task, acoustic stimuli were
delivered binaurally through foam stereo eartips (ER3-
15A) using the Stim Audio System (P/N 1105), and con-
sisted of 1000 Hz (target) and 500 Hz (nontarget) 80 dB
tones (500 ms duration, 10 ms rise/fall time). For each
of these tasks, a randomised stimulus sequence consisting
of 200 trials was presented (target p = .2, nontarget p = .8)
with an ISI of 1.5 s in a single block that was
approximately 5 min in duration. Targets were responded
to with a button press using the Stim System Switch
Response Pad (P/N 1141).
Cardiovascular measures
Aortic and peripheral measures of pulse pressure, and
resting HR were assessed using an electronic sphygmo-
manometer and tonometer (AtCor Medical Sphygmo-
Cor CVMS v8.2); the mean across three consecutive
measurements of each index was computed. To ensure
reliability, only measurements equal to or greater than
an Operator Index of 80 were used. The Operator
Index is a measure of quality control derived from the
mean and variability in pulse strength, diastolic vari-
ation, and systolic shape deviation. The score is out of a
possible 100, and an Index over 80 is considered
acceptable.
Procedure
Participant eligibility was confirmed during a brief
telephone interview. Then, during a screening session,
participants provided informed consent and completed
the MMSE before a medically trained professional con-
ducted a medical questionnaire, physical examination,
and provided participants with a pathology request
form so that blood samples could be taken and analysed
at a Douglas Hanley Moir pathology laboratory. Blood
sampling was only deemed necessary for participants
aged 50–75; pathology examined were full blood count,
and liver and kidney function. If no abnormalities were
discovered participants completed a training session on
the Compass test battery, and were randomly allocated
to a treatment group via a computer randomisation
package. The randomisation was conducted by the re-
search program coordinator externally to the research
team and the assignments were blinded to all investiga-
tors and assessors as well as to the trial participants.
All data were collect at the National Institute of
Complementary Medicine Clinical Laboratory, Western
Sydney University during 2012–2013.
At the beginning of each of the one-week interven-
tion cycles, participants attended a baseline session
where they were asked a series of questions about any
illnesses or adverse events, and whether they had
started, stopped, or changed any medications. Then,
whilst sitting comfortably, participants had their cardio-
vascular measurements taken, completed the Compass
testing battery, were fitted with EEG recording appar-
atus, and had their EEG activity recorded. Each of these
baseline sessions ran for approximately 2.5 h. Efforts
were made to ensure that each timepoint for each
participant was at the same time of day. Participants
were dispensed eighteen capsules containing either the
SLT formulation or placebo (depending on randomisa-
tion) and were instructed to take two capsules per day
for one week (morning and night with food), and to re-
turn any unused capsules at the post-treatment session.
Four extra capsules were provided in the event that
participants were unable to attend the next scheduled
appointment. Halfway through the treatment cycle, a
brief telephone follow-up was conducted to ensure
participant safety in regards to adverse reactions and
illness, and to confirm the time and date of the next
testing session. The post-treatment sessions were iden-
tical to the baseline, with the exception that partici-
pants returned any excess capsules and also completed
a short survey to determine the successfulness of the
blinding procedure.
After the initial intervention cycle, there was a seven
day washout period to allow for the elimination of any
residual herbal compound from the body. Following this,
participants began a second week of treatment in which
they received the counterbalanced treatment condition
(SLT or placebo), and again were tested pre- and post-
intervention cycle.
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EEG data extraction and quantification
Using Neuroscan Edit software (Compumedics, Ver-
sion 4.3.1), the EEG data were EOG artefact [40] and
DC-offset corrected, and low-pass filtered at 30 Hz
(24 dB/Octave). Any additional artefacts exceeding ±
100 μV were excluded. Oddball task data were epoched
from 200 ms pre- to 1400 ms post-stimulus and base-
line corrected using the pre-stimulus period. Trials
containing omission (misses) and commission (false
alarms) errors were excluded. For each subject and
each modality, averages were computed for each of the
four treatment sessions and the two stimulus condi-
tions. Averaged half-sampled data (epoched −100 to
600 ms: 350 datapoints) from 18 scalp locations were
submitted to two separate temporal Principal Compo-
nents Analyses (PCAs; one for each modality) using
the ERP PCA toolkit (v. 2.23 [32]) in MATLAB (The
Mathsworks; Version 8.0.0.783, R2012b). In each of the
PCAs, factors for all conditions were quantified simultan-
eously (2304 observations: 16 participants × 2 stimulus
conditions × 4 testing sessions × 18 electrodes). The
PCAs used the unstandardised covariance matrix with
Kaiser normalisation, and all 350 unrestricted factors
underwent Varimax rotation [41]. PCA factors were
identified as ERP components based on their latency,
topography, and polarity of their conspicuous max-
imum loading. The peak amplitude of each identified
component was output and entered into subsequent
statistical analyses.
The 5 min of artefact-corrected data from each of the
resting conditions were epoched to 2000 ms and then
quantified in MATLAB and EEGLAB (Version 9.0.8.6b
[42]). For each subject and each condition, spectral am-
plitudes were computed using discrete Fast Fourier
Transforms with a 10 % Hanning window for each of
the four treatment sessions. Frequency data from 0 to
30 Hz were extracted with a resolution of 0.5 Hz, before
averaging across epochs. The spectral band amplitudes
were calculated by summing the activity across the fre-
quency bins for delta 0.5-3.5 Hz, theta 4.0-7.5 Hz, alpha
8.0-13.0 Hz, and beta 13.5-29.5 Hz.
Statistical analyses
As this was a pilot trial, no formal sample size calcula-
tion was made. Sample size was approximated based on
a trial [65] which employed two of the three SLT constit-
uents as a combined intervention using a similar cross-
over design. A post-hoc sample size calculation showed
that in order to detect a difference of d = 1.00 at 80 %
power, two-tailed, α = .05, 17 participants were required,
suggesting that the sample size used here, although
small, was sufficient to detect a meaningful change in
the primary outcome measure.
Cognitive and cardiovascular measures
Relevant outcome measures were recorded automatically
by the Compass and SphygmoCor software. Separate
repeated measures analyses of variance (ANOVAs) with
Treatment (SLT vs. placebo) and Time (baseline vs. post-
treatment) as within-subject factors was used to com-
pare the effects of SLT with placebo for each of the
Compass and cardiovascular measures. As this was a
pilot study, results approaching significance (p < .10) are
reported as they may potentially reflect the existence of
real effects.
EEG and ERPs
Expected EEG band and ERP component topographies
were defined by selecting a cluster of electrodes sur-
rounding the site of maximal amplitude. Using a mean
across a region defined by multiple sites, rather than a
single electrode, reduces the impact of chance variance
at a single site [43].
Separate repeated-measures MANOVAs then assessed
each band and component’s amplitude for the effects of
Condition (EEG: eyes open vs. eyes closed; ERPs: target
vs. nontarget), Treatment (SLT vs. placebo) and Time
(baseline vs. post-treatment). Cohen’s d effect sizes are
reported. The violations of sphericity assumptions asso-
ciated with repeated-measures analyses do not affect
single degree of freedom contrasts, so Greenhouse-
Geisser-type correction was not necessary [44]. All F-
tests reported have (1, 15) degrees of freedom.
One-way tests were utilised for all analysed predic-
tions. It should also be noted that, as this paper details
results for a number of dependent measures, the
frequency of Type I errors increases. However, this in-
crease in frequency of Type I errors cannot be con-
trolled by adjusting α-levels, because the probability of
Type I error remains the same [45].
Results
As shown in Fig. 1, a total of 39 individuals expressed
interest in the trial with 17 individuals randomised and
22 excluded due to failure to meet inclusion/exclusion
criteria or availability constraints. Demographics and
clinical characteristics of the 16 participants that
completed the trial are presented in Table 1.
Cognitive function
Table 2 displays the mean and standard error across sub-
jects before and after treatment with SLT and placebo
for each of the Compass tasks, together with measures
of fatigue and alertness. Two of the Compass tasks
showed effects of SLT that approached statistical signifi-
cance. For the Alphabetic Working Memory Task, a
decrease in reaction time from baseline to post-
treatment was larger for SLT than placebo (F = 3.72,
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p = .073, d = 1.00). SLT also enhanced N-Back task per-
formance, with greater accuracy reported after treatment
(cf. baseline) with SLT than placebo (F = 4.35, p = .054,
d = 1.09). The other Compass tasks and VAS mood and
alertness scales did not show an effect of SLT (no treat-
ment × time interaction).
ERP components
Figure 2 illustrates the grand mean ERPs for targets and
nontargets (solid lines) from midline sites (left: visual;
right: auditory).
For the visual task PCA, factors 1–4 and factor 6
accounted for 84.9 % of the total variance, and for the
auditory task PCA, the first 5 accounted for 87.8 % of
the variance; these factors were extracted and retained
for analysis. The sum of these extracted factors is illus-
trated in Fig. 2 (dashed lines) for each modality. When
correlated across the midline, the reconstructed and ori-
ginal waveforms were highly similar for visual targets,
r(1048) = .97, p = < .001, and nontargets, r(1048) = .92,
p = < .001, and for auditory targets, r(1048) = .99, p = <
.001, and nontargets, r(1048) = .98, p = < .001.
For each modality, the temporal factor loadings
(rescaled to μV by multiplying each time point by the
standard deviation [46]) for each of the ERP components
are displayed as a function of time in Fig. 3. Topographic
headmaps of the temporal components, averaged across
treatment, time, and stimulus condition are displayed
above the factor loadings for each of the modalities.
Component labels, site of maximal amplitude, percent-
age of variance explained, and sites selected for analysis
for each of the rotated components are indicated in
Table 3. Components were labelled according to their
polarity, latency, temporal sequence, comparison with
the raw ERPs (see Fig. 2), and topography.
Table 4 details the mean and standard error across sub-
jects for each analysed visual (middle) and auditory
(lower) ERP component (targets and nontargets), at base-
line and post-treatment, for both SLT and placebo. As
shown in Table 4, amplitudes were significantly greater for
targets than nontargets for visual N1 (F = 20.70, p < .001,
d = 2.35), N2 (F = 20.60, p < .001, d = 2.35), and P3b
(F = 34.26, p < .001, d = 3.06). There were no effects or
Fig. 1 Flow chart of the study participants
Table 1 Baseline demographics and clinical characteristics of
participants
Demographics Mean ± Standard Deviation
Age (years) 49.19 ± 14.28
Height (cm) 169.29 ± 9.35
Weight (kg) 70.50 ± 18.56
MMSE 29.50 ± 0.60
Pulse (bpm) 68.82 ± 14.27
Blood Pressure Systolic (mmHg) 118.71 ± 19.02
Blood Pressure Diastolic (mmHg) 76.29 ± 9.80
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interactions involving treatment and time for any of
the visual ERP components.
Table 4 also illustrates significantly larger amplitudes
to targets than nontargets for auditory N2 (F = 17.14,
p = .001, d = 2.12), P3a (F = 10.61, p = .005, d = 1.67),
and P3b (F = 88.73, p < .001, d = 4.96). As shown in
Fig. 4, auditory target N1 was smaller following SLT com-
pared to placebo (from baseline to post-treatment) than
nontarget N1 (F = 6.39, p = .023, d = 1.31). For auditory
P3a, the target enhancement showed a greater increase
after treatment (cf. baseline) with SLT in comparison to
placebo that approached significance (F = 3.15, p = .096,
d = 0.91; see Fig. 4). Topographic headmaps (Fig. 4)
illustrate that these differences were largest centrally
and on the left. There were no other treatment × time
interactions for the other auditory ERP components.
EEG spectral bands
Delta and theta had a strong midline topography (defined
as mean across Fz, Cz, Pz), and alpha and beta were both
largest at parietal sites (mean across P3, Pz, P4). The
across-subjects means and standard errors for each of the
EEG bands, before and after both treatments, are detailed
in Table 4, separately for eyes open and eyes closed condi-
tions. Table 4 shows that amplitudes were greater for eyes
closed than eyes open for both theta (F = 17.92, p = .001,
d = 2.17) and alpha (F = 5.43, p = .034, d = 1.22) bands.
There were no significant main effects or interactions for
delta or beta. Treatment with SLT did not affect resting
EEG amplitude for any of the four bands.
Table 2 Mean difference and standard error between the SLT
and placebo treatments for each Compass task
Compass Task Mean Difference ± Standard
Error
Immediate Word Recall (number correct) 0.19 ± 0.04
Delayed Word Recall (number correct) 0.69 ± -0.03
Word Recognition (number correct) -0.06 ± 0.24
Picture Recognition (number correct) -0.5 ± 0.23
Face Recognition (number correct) 0.31 ± -0.11
Simple Reaction Time (ms) 6.07 ± 7.54
2 Choice Reaction Time (accuracy %) -0.88 ± 0.59
2 Choice Reaction Time (ms) 21.36 ± 11.82
4 Choice Reaction Time (accuracy %) 0.26 ± -0.18
4 Choice Reaction Time (ms) -18.68 ± 0.68
Numerical Working Memory (accuracy %) 3.34 ± -1.12
Numerical Working Memory (ms) 90.09 ± 60.33
Alphabetic Working Memory (accuracy %) 0.13 ± -1.09
Alphabetic Working Memory (ms) -44.14 ± -19.78
Corsi Block Span (Span Length) 0.25 ± -0.01
N-Back (accuracy %) 4.17 ± -0.82
Serial Subtract 3 (number correct) 1.63 ± -0.82
Serial Subtract 7 (number correct) -0.94 ± -0.27
Rapid Visual Information Processing
(accuracy %)
-2.16 ± 0.13
Rapid Visual Information Processing (ms) 40.67 ± -16.79
Mental Fatigue (End - Start) -0.63 ± -2.32
Alertness (End - Start) 1.89 ± 0.40
Note: Tasks that are bolded had a treatment × time interaction that
approached statistical significance (p < .10)
Fig. 2 Grand mean ERPs for targets and nontargets from the midline sites for both visual (left) and auditory (right) modalities. The solid lines represent
the raw data, and the dashed lines illustrate the reconstructed PCA waveforms. PCA extracted components are labelled at Fz for both modalities
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Fig. 3 Factor loadings for visual (top) and auditory (bottom) modalities. The topographic headmaps for each of the extracted ERP components
are shown above the factor loadings (averaged across all subjects, treatments, and testing sessions), separately for each modality
Table 3 Information for the factors identifiable as ERP components
Visual TF004 TF006 TF002 TF003 TF001
Component N1 P2 N2 P3a P3b
Latency (ms) 168 208 252 352 420
Maximal Site P3 O2 P4 P1 C2
Variance (%) 3.8 2.5 16.6 16.3 45.8
Sites Analysed P3, P4 Fz C3, Cz, C4 Fz, Cz, P3, Pz, P4 Cz, Pz
Auditory TF005 TF004 TF002 TF003 TF001
Component N1 P2 N2 P3a P3b
Latency (ms) 132 210 264 348 412
Maximal Site F2 Cz Fz Fz Pz
Variance (%) 4.7 6.6 10.9 8.3 57.4
Sites Analysed F3, Fz, F4, Cz Fz, Cz F3, Fz, F4, C3, Cz, C4 F3, Fz, F4 P3, Pz, P4
Note: Rows indicate component name, latency, site of maximal amplitude, percentage of total variance explained, and sites selected for analysis.
TF = Temporal Factor
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Cardiovascular measures
Mean peripheral and aortic pulse pressure (mmHg;
systolic minus diastolic difference), and HR (bpm) for
placebo and SLT at baseline and post-treatment are
detailed in Table 5. Treatment with SLT compared to
placebo did not affect any of the three cardiovascular
measures.
Adverse effects
No serious adverse events were noted in this study.
Minor adverse events outlined in Table 6 were noted
during each cycle of the trial. One participant with-
drew from the trial during the first intervention-cycle
due to mild gastrointestinal symptoms which coincided
with a probably unrelated upper respiratory infection.
Symptoms were rated as moderate severity, onset was
noted after two doses, and duration was three to four
days. The participant was found to be treated with the
placebo suggesting that these effects were unrelated to
the trial.
Discussion
This pilot study investigated the effect of SLT on neuro-
cognitive and cardiovascular functioning in healthy
adults. Participants were assessed before and after one
week of treatment with 2 capsules of SLT (60 mg stan-
dardised extract per capsule) and placebo per day, sepa-
rated by a one week washout period. Primary outcome
Table 4 Mean difference and standard error between the SLT
and placebo treatments for each EEG band and ERP component
(all μV)
Mean Difference ± Standard Error
EEG Spectral Band Eyes Open Eyes Closed
Delta -1.64 ± -0.01 -0.07 ± -0.73
Theta -0.82 ± -0.37 0.20 ± -0.32
Alpha -0.16 ± 0.44 -3.66 ± -0.94
Beta 2.14 ± 0.82 -0.65 ± -0.5
Visual ERP Component Target Nontarget
N1 -1.72 ± -0.06 -0.45 ± -0.17
P2 -0.37 ± -0.08 -0.69 ± 0.02
N2 -0.74 ± -0.06 -0.05 ± -0.26
P3a 2.58 ± 0.02 1.98 ± -0.20
P3b -1.12 ± 0.10 -1.38 ± -0.04
Auditory ERP Component Target Nontarget
N1 2.14 ± 0.11 -1.38 ± -0.14
P2 1.16 ± 0.84 -1.02 ± -0.31
N2 -0.14 ± 1.78 -0.04 ± -0.13
P3a 3.65 ± 0.07 -0.36 ± -0.08
P3b 0.58 ± -0.25 -2.27 ± 0.10
Note: The bolded ERP components had a treatment × time × stimulus type
interaction (p < .10)
Fig. 4 Mean difference topographic headmaps for auditory N1 and P3a. Headmaps illustrate the difference in stimulus condition (target minus
nontarget) and the difference between sessions (post-treatment minus baseline) for placebo and SLT. A SLT related reduction in N1 negativity,
and an increase in P3a positivity are apparent
Table 5 Mean difference and standard error between the SLT
and placebo treatments for each of the three cardiovascular
measures
Mean Difference ± Standard Error
Peripheral Pulse Pressure (mmHg) -1.20 ± 0.52
Aortic Pressure (mmHg) -2.50 ± 0.19
Resting HR (bpm) 1.07 ± 1.55
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measures were scores on a computerised neuropsycho-
logical test battery, and oddball task ERP component
amplitudes. Secondary outcome measures were resting
EEG band amplitudes and cardiovascular measures of
central and peripheral pulse amplitude, and resting HR.
There was a trend towards improvements in alphabetic
working memory and visual working memory with SLT
compared to placebo. Auditory P3a amplitudes were
slightly larger following SLT than placebo for targets
compared to nontargets, and a similar target enhance-
ment showed a decrease following SLT for auditory N1.
SLT did not significantly affect resting state EEG activity
or cardiovascular system function.
On the Compass neuropsychological test battery, reac-
tion time on the Alphabetic Working Memory Task and
accuracy on the N-Back task both showed modest im-
provements following treatment with SLT, compared to
placebo, suggesting that SLT may have the potential to
improve working memory performance in healthy adults.
Previous work has indicated that two of the constituents
of SLT, Ginkgo biloba and Panax ginseng, have a similar
effect on memory, with a large study (N = 256) showing
significant improvements in numerical and spatial work-
ing memory after a 12 week trial of a ginkgo/ginseng
combination [47]. A similar 30 day trial on adults [48]
demonstrated significant improvements in working
memory (along with processing speed and other aspects
of executive function) following treatment with 120 mg
Ginkgo biloba in comparison to placebo. Compared to
the current pilot study, these previous studies used lar-
ger samples (N = 16 vs. N = 61–256) and different treat-
ment doses (120 mg vs. up to 320 mg) for longer
periods (1 week vs. 4–12 weeks), suggesting that the ef-
fect of SLT could be much greater given an increase in
these parameters. In the current study, no effect of SLT
was found on other Compass measures including Imme-
diate and Delayed Word Recall, Word Recognition,
Simple and Choice Reaction Time, Numeric Working
Memory, Corsi Block Span, Picture Recognition, Face
Recognition, Serial Subtraction, and the RVIP task, or
on the mood and alertness scales.
From the visual and auditory oddball tasks, five ERP
components were identifiable from each of the unre-
stricted temporal PCAs: N1, P2, N2, P3a, and P3b. Vis-
ual N1, N2, and P3b, and auditory N2, P3a, and P3b
were all larger to targets than nontargets. These findings
are broadly similar with previous oddball studies [49–
54]. As the purpose of this study was to evaluate the ef-
fects of SLT, these target/nontarget differences together
with the components that were not sensitive to treat-
ment with SLT (visual N1, P2, N2, P3a, and P3b, and
auditory P2, N2, and P3b) will not be discussed further.
Target N1 was smaller following SLT compared to
placebo (from baseline to post-treatment) than nontarget
N1. This is a novel finding that has not been reported
elsewhere in the literature. To the best of our know-
ledge, only one other study has examined changes in N1
amplitude after treatment with any SLT constituents. In
that study [53], no changes in auditory oddball N1, P2,
N2, or P300 amplitudes were reported after acute and
chronic doses of Ginkgo biloba. The N1 component
elicited in the current study had a strong fronto-central
topography and latency (132 ms) suggestive of N1
Component 1 [54]. This component is generated in the
supratemporal plane of the primary auditory cortex [55],
and it is thought to facilitate the conscious perception of
auditory stimuli [50]. A reduction in amplitude indicates
less activation in these regions. Although it is difficult to
speculate about any functional significance of this
treatment-related change, findings might reflect more
efficient attentional processing of auditory information.
Auditory P3a amplitudes trended towards being
larger following SLT than placebo for targets compared
to nontargets; another novel finding. P3a, is elicited to
attention-capturing stimuli [56, 57] and is thought to
relate to working memory processes [58], with evidence
from lesion studies suggesting that its neural generators
are located in the frontal lobe, hippocampus, and thal-
amus [59; for a review see 60]. Speculatively, and when
viewed in conjunction with the Compass test findings, this
SLT-related enhancement in P3a amplitude, may repre-
sent increased working memory activation. It should also
be noted that an analysis of P3a has not been reported in
similar herbal medicine work as most studies quantify
component amplitudes using baseline-to-peak measures.
It is important to investigate overlapping components
using techniques such as PCA (as done in the current
study) in order to fully understand the (often subtle) ef-
fects of various interventions. There were no SLT
treatment-related effects on the other visual and auditory
ERP component amplitudes.
The topographic distribution for each of the EEG bands
was in line with previous work examining resting condi-
tion amplitudes [61]. Delta and theta were largest at the
midline, and alpha and beta were both maximal parietally.
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Typical condition-related changes in amplitudes were ap-
parent with larger amplitudes for eyes closed than eyes
open for theta and alpha bands; a pattern of results
broadly in line with other work [62–63]. Treatment with
SLT did not have an effect on resting EEG activity.
Mean aortic and peripheral pulse pressure, and resting
HR did not show any changes with SLT treatment. This
is not surprising given that the current study recruited
healthy adults, and special care was taken to ensure that
older participants, who are at increased risk of cardio-
vascular disease, had a full blood count that was within
normal limits.
Limitations and future directions
This was the first study to assess SLT, a formula with a
unique combination of three herbs, in a healthy cohort.
Compared to this study, previous work [47, 48] using
Ginkgo biloba and/or Panax ginseng found significant
improvements in a range of executive functions, such as
episodic memory, in addition to improved mood and
arousal (for a review see [64]). Those studies used larger
sample sizes (N = 61–256), longer interventions (4–12
weeks), and larger treatment doses (up to 320 mg per day)
than the current study. Given the substantial preclinical
work showing the potential benefits of SLT, and the
increase in therapeutic effects due to synergism, further
research in a larger cohort is needed, with increases in the
parameters mentioned above.
Future work is also required to replicate the novel N1
and P3a amplitude findings, and should also include
latency analyses. Previous research [52, 65] has reported
changes in latency, rather than amplitude, however,
latency analyses are not possible with temporal PCA.
Future work could complement PCA analyses with Resi-
due Iteration Decomposition (RIDE) analysis, which uses
latency variability to estimate single trial latencies with a
high degree of precision [66–68]. A study combining
these analyses would be able to examine any treatment-
related changes in ERP components effectively.
As with the neurocognitive measures, the dose and
treatment length of SLT were probably too small to affect
cardiovascular parameters in healthy adults. Further, there
is some evidence suggesting that acute, rather than
chronic, administration of ginkgo may produce larger
effects. For instance, another study employed radial pulse
wave analysis to measure reflection, stiffness, and periph-
eral augmentation indices and reported improvements in
the stiffness index 2 h after treatment [69]. Future work
could examine both the acute and chronic effects of SLT
on cardiovascular function in healthy adults.
Conclusions
Although the observed effects of SLT were small, find-
ings indicate that SLT has the potential to improve
working memory performance in healthy adults. A larger
sample size, and possibly a higher dose of SLT over a
longer period are needed to extend upon these results. A
dose escalation study to determine the appropriate dos-
age for cognitive benefits is recommended. The possible
benefits of SLT should also be explored in healthy older
adults, and individuals with mild cognitive impairment.
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